Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

65.68 +0.01 (+0.02%)
Streaming Delayed Price Updated: 9:49 AM EST, Dec 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 153,689
Open 65.88
Bid (Size) 65.66 (200)
Ask (Size) 65.99 (100)
Prev. Close 65.67
Today's Range 65.42 - 66.37
52wk Range 29.31 - 69.33
Shares Outstanding 95,640,600
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire

Performance

YTD
+34.2%
+34.2%
1 Month
+9.2%
+9.2%
3 Month
+26.1%
+26.1%
6 Month
+98.2%
+98.2%
1 Year
+30.1%
+30.1%

More News

Read More
News headline image
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims
From Grabar Law Office
Via GlobeNewswire
News headline image
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Ibotta, Inc. (NYSE: IBTA); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Inspire Medical Systems, Inc. (NYSE: INSP); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on
From Grabar Law Office
Via GlobeNewswire
News headline image
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Ibotta, Inc. (NYSE: IBTA); and Stride, Inc. (NYSE: LRN): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Ibotta, Inc. (NYSE: IBTA); and Stride, Inc. (NYSE: LRN): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
What Does the Market Think About Cytokinetics Inc? ↗
Via Benzinga
News headline image
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); enCore Energy Corp. (NASDAQ: EU); Fluor Corporation (NYSE: FLR); Fortrea Holdings, Inc. (NASDAQ: FTRE); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating
From Grabar Law Office
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Urgently Reminds Investors of Cytokinetics, Quanex, Freeport, and Primo Brands to Contact the Firm About their Rights
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
CYTK FINAL DEADLINE: Faruqi & Faruqi, LLP Announces that Cytokinetics Investors Have Opportunity to Lead Class Action Lawsuit
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Cytokinetics, Incorporated Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTK
Via TheNewswire.com
Topics Earnings Fraud Lawsuit
News headline image
Cytokinetics, Incorporated Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTK
Via NewMediaWire
Topics Earnings Fraud Lawsuit
News headline image
Cytokinetics 72 Hour Deadline Alert: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Urgently Reminds Investors of Cytokinetics, Quanex, Freeport, and Primo Brands to Contact the Firm About their Rights
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Deadline Soon: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Cytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, Incorporated - CYTK
From SkyMedia, LLC
Via GlobeNewswire
News headline image
Shareholders of Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTK
Via TheNewswire.com
Topics Earnings Fraud Lawsuit
News headline image
Shareholders of Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTK
Via NewMediaWire
Topics Earnings Fraud Lawsuit

Frequently Asked Questions

Is Cytokinetics, Incorporated - Common Stock publicly traded?
Yes, Cytokinetics, Incorporated - Common Stock is publicly traded.
What exchange does Cytokinetics, Incorporated - Common Stock trade on?
Cytokinetics, Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cytokinetics, Incorporated - Common Stock?
The ticker symbol for Cytokinetics, Incorporated - Common Stock is CYTK on the Nasdaq Stock Market
What is the current price of Cytokinetics, Incorporated - Common Stock?
The current price of Cytokinetics, Incorporated - Common Stock is 65.68
When was Cytokinetics, Incorporated - Common Stock last traded?
The last trade of Cytokinetics, Incorporated - Common Stock was at 12/08/25 09:49 AM ET
What is the market capitalization of Cytokinetics, Incorporated - Common Stock?
The market capitalization of Cytokinetics, Incorporated - Common Stock is 6.28B
How many shares of Cytokinetics, Incorporated - Common Stock are outstanding?
Cytokinetics, Incorporated - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.